• Skip to content

Biotech Animated

Biotech Animated | Biotechnology & Life-Science Animation | Beautifully Deliver Your Life-science Company’s Message to a Greater Audience | Biotech Animated is a Life-Science Animation, Advertising Strategy and Business Development Firm

Main navigation

  • Projects
  • About
  • What We Do
  • Why Video
  • Team
  • Contact Us

How 50 Cows are redefining drug discovery

*Please scroll down to the bottom of the page for the final deliverable.

Project Overview

SAB Biotherapeutics is a biopharmaceutical company delivering the world’s first large scale platform to create fully human polyclonal antibodies.

At the time of this production the industry hasn’t caught up with the value of polyclonal antibodies from the sense that this is the most normal way in which our bodies fight disease, in addition to the fact that polyclonal antibodies have other properties that are not mimicked by monoclonal antibodies or monoclonal antibody cocktails.

Frequent questions SAB is asked are: “how can you guarantee consistency lot to lot” and “if only 5% of the polyclonal mixture is targeted don’t you need 20 times more for it to be as effective as a monoclonal antibody.”

Biotech Animated was commissioned to create an educational video presentation designed to be displayed on the homepage of SAb Biotherapeutics. The video explains the advantages that polycolonal antibodies have over monoclonal antibodies. For example, fully human antibodies can be more effective, last longer, have fewer side and provide immediate protection or passive immunity.

The target audience will be investors, collaborators, and other large biotechnology companies. The goal of the video will be to attract interest in the therapeutic use of human polyclonal antibodies and the bovine production platform.

Additional points of interest for this project were:

  • It’s not often realized that there are far more polyclonal antibody products on the market than monoclonal.
  • SAB Biotherapeutics owns all the IP for producing fully human antibodies in cows.
  • From a single cow they can produce 600g of antibody per month. SAB

Biotherapeutics currently owns 50 cows and therefore has a large production capability.

Storyboard

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 01

75 days to a potential cure
From initial inoculation to purified, clinic-ready cGMP therapeutics

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 02

How 50 cows are redefining drug discovery and development

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 03

What if the drug discovery and development process could be compressed to

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 04

Only 75 days from target identification to animal trials?

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 05

No antibody screening, straightforward scale-up, and little hands-on time.

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 06

This is the vision that the team at SAb Biotherapeutics has already turned into a reality.

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 07

And it's all thanks to a small herd of cows that has been engineered to produce fully human antibodies.

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 08

The workflow is simple and can be completed in as little as 75 days.

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 09

Step 1: Inoculate the cows with the potential drug target, such as viral capsid protein or tumor antigen.

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 10

Step 2: Wait for their engineered immune system to start developing antibodies to the target.

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 11

Step 3: Harvest plasma.

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 12

Step 4: Purify the polyclonal antibodies.

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 13

Step 5: Test for potency.

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 14

At the end of the 75 days

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 15

As many as tens of thousands of doses of cGMP-compliant polyclonal antibodies are ready for

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 16

Animal testing, clinical trials, or as approved therapeutic.

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 17

Why polyclonal antibodies?

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 18

Polyclonal antibodies are an excellent therapeutic choice for indications such as infectious diseases, oncology, autoimmunity, and inflammation.

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 19

The power of polyclonal antibodies lies in their broad multi-component activity.

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 20

While monoclonal antibodies are chosen for specific, high-affinity binding

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 21

Polyclonal preparations consist of a mixture of antibodies that bind to different areas on the antigen at both high and low affinities.

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 22

Adding together all the high and low affinity binding in the preparation leads to high potency.

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 23

In addition, because polyclonal preparations bind to multiple regions on the antigen

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 24

They are able to form an immune complex lattice, which monoclonal antibodies cannot.

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 25

This immune complex lattice is more efficiently removed by

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 26

Phagocytes, again increasing the potency of polyclonal preparations.

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 27

Despite these advantages, the polyclonal antibodies of the past have carried

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 28

The risk of adverse effects.

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 29

Many are intact antibodies, and their non-human protein sequences can elicit serum sickness and anaphylaxis.

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 30

SAb Biotherapeutics engineered cows overcome this problem

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 31

By producing fully human antibodies, bringing the power of polyclonal antibodies to life.

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 32

Ten cows. 75 days. Tens of thousands of doses of potent, clinic-ready, fully human therapeutic antibody.
With a well-established regulatory path under FDA CBER.

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 33

Imagine the possibilities.

SAb Biotherapeutics Cows Drug Discovery Video Storyboard 34

Work with SAb Biotherapeutics for more efficient discovery and development.

Final Deliverable

  • Careers
  • Contact Us

COPYRIGHT © 2021 BIOTECH ANIMATED